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Background: The research for procathepsin B and endogenous
inhibitors of cysteine proteases in tumor markers of human
reproductive system is important for early diagnostics of cancer.
Preform of cathepsin B and cystatins B and C also are universally
involved into development of different tumors. Tumor cells as
well as tumor-associated macrophages have been shown to
secrete active forms of proteases and their inhibitors; however,
their roles, especially those of proenzymes as markers of
malignancy, are still under investigation.
Aim: to evaluate procathepsin B and endogenous inhibitors of
cysteine proteases cystatins B and C in tumors of reproductive
system.
Materials and methods: Serum and ascites fluid of 38 patients
with ovarian cancer (among them 15 patients after treatment)
and benign ovarian tumors (n = 9), endometrial cancer (n = 31,
before treatment 14), mammalian cancer (n = 29, before treat-
ment 18) of stages II–IV for all groups, from Department of Gyne-
cology of Regional Oncology Center, Novosibirsk, were under
investigation. Serum of practically healthy women aged 18–80
(n = 82) from Regional Diagnostic Center, Novosibirsk, was used
as a control group. Serum of women with tumors of the reproduc-
tive system and ascites fluids of women with ovarian tumors
(aged 18–80 years), before operation were used for assay of pro-
cathepsin B, cysteine protease inhibitors cystatins B and C. Serum
procathepsin B concentration was measured by ELISA commer-
cial kit for human (R&D) USA; cystatin C using BioVendor com-
mercial kits (Czechia), cystatin B – with help of ELISA kits for
human (USCN Life Science Inc., Wuhan, China). Common biomar-
ker of ovarian cancer, CA-125, was assayed by using a commercial
kit (Vector, Koltsovo, Novosibirsk Region, Russia). Statistical anal-
ysis performed by one a way ANOVA Statistic 12, program with
help of Kruskall–Wallis test and the Mann–Whitney U test used
to assess differences in procathepsin B or cystatins B and C levels
between patient groups. Statistical analysis was performed with
the soft package Statistics 12, with the level of significance being
set at <0.05.
Results: In serum of patients with endometrial cancer, ovarian
cancer, mammalian cancer – significant increases in serum pro-
cathepsin B (p < 0.001), cystatin B (p < 0.05) and CA-125
(p < 0.001) were noted. However, in patients with benign tumor
increased serum common tumor marker CA-125 (p = 0.005 vs.
healthy controls) was shown without any changes in serum level
of procathepsin B, cystatins B and C. Concentrations procathepsin
B and Cystatin B in serum and ascites of patients with ovarian
tumor was used to assess differences in procathepsin B or cys-
tatins B and C levels between groups. Serum procathepsin B
(p < 0.05) and in ascites fluid of patients with ovarian cancer
(p < 0.001) was shown to significant increase in ovarian cancer
group vs. benign ovarian tumors group. The concentration of
CA-125 in ascites of patients with ovarian cancer (p < 0.000) and
benign ovarian tumors (p < 0.05) was high, but has not differences
between them (p > 0.1).
Conclusion: One can conclude that serum procathepsin B and
endogenous inhibitors of cysteine proteases cystatin B are
prospective tumor biomarkers in reproductive system tumors.
Procathepsin B and cystatin B seem to be important in differential
diagnosis of ovarian cancer and benign ovarian tumors. Pro-
cathepsin B and cystatin B are involved in breast and endometrial
cancer that warrants further investigation of their role in cancer.
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Tumor-associated neutrophils (TANs) are the cell population
that differs in morphofunctional characteristics from peripheral
blood cells (Gregory and Houghton, 2011). The first study to iden-
tify the presence of TANs as an independent poor prognostic fac-
tor and to include TANs into a prognostic risk model was
published in 2006 (Donskov , 2006). Specific signals during cancer
progression have been shown to induce the emergence of a pro-
tumor phenotype of neutrophils (PMN). Frinlender (2013) points
out an anti-tumor phenotype of TANs. Of particular interest is
the study of interaction of neutrophils with T cells because the
latter are considered to be cytotoxic cells mediating antitumor
immunity. The aim of the study was to assess the lymphoid cell
infiltration (LCI) and the functional status of TANs in ovarian
cancer. LCI was assessed by immunohistochemistry and the
levels of mieloproxydase (MPO) and cationic proteins (CP) were
evaluated by cytochemical methods in ovarian carcinoma surgi-
cal resection specimens. The results were presented as a mean
cytochemical coefficient (MCC). The intensity of nitroblue
tetrazolium (NBT) test was expressed as a percentage. Obtained
results were analyzed by nonparametric statistical methods.
The Kruskal–Wallis test was used to evaluate the differences
between groups.
We established that low intensity of infiltration in general and
formation of marginal lymphoid cell ridge in some tumors are
typical for malignant ovarian neoplasms. More intensive infiltra-
tion was found in the regions of the rapid growth of tumor cells,
i.e. invasion zone. In some cases, a group of tumor cells was sep-
arated from the main part of the parenchyma and surrounded by
lymphoid elements. Conditions are created under which active
spread of cancer cells in the parenchyma is associated with inten-
sive lymphoid cells infiltration in the stroma. Total count and
density of lymphoid cells can significantly vary: from single
lymphoid elements uniformly scattered in the tumor tissue to
focal accumulations. In tumor tissue location of lymphoid cells
is irregular, so most of the infiltration is in the stroma and among
the cancer cells only solitary lymphocytes are found. Lymphoid
cells which make up the infiltration include 12.3 ± 1.52% of
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macrophages, 22.1 ± 2.3% of plasma cells, 62.5 ± 1.1% of lympho-
cytes and 3.1 ± 0.9% of PMN. Total amount of cells was 224.1
± 32.8 per 1 mm2 of tumor.
Lymphocytes in ovarian carcinomas do not form large clus-
ters; they are disposed among other lymphoid cells in the stroma
on the periphery of the tumor. Plasma cells have a classical mor-
phological structure and often locate in the stroma and on the
periphery of the tumor. Macrophages are an integral part of the
tumor infiltrate. In the tumor they become stretched and angular.
Macrophages usually have large dimensions, and they are located
in the stroma as well as in the parenchyma among the cancer
cells. Segmented leukocytes (presented in the vast majority by
neutrophils) are constantly found in the infiltrate of the stroma
and the parenchyma, most often they are found near or among
massive necrosis.
Analysis of TANs functional activity in comparison with the
peripheral blood neutrophils has shown that MPO activity
elevated and amounted 2.21 ± 0.43 MCC against 1.40 ± 0.07 MCC
in the peripheral blood neutrophils, the level of CP also increased
and amounted 1.51 ± 0.39 MCC against 0.83 ± 0.43 MCC. TANs
activity in NBT-test was not significantly different from that of
the peripheral blood neutrophils.
TANs compose the minor part of primary ovarian tumor infil-
trate. Indicators of aerobic and anaerobic bactericidal activity of
TANs significantly exceed that of the peripheral blood neutrophils
in patients with ovarian cancer.
This work was conducted in the framework of implementing
the state assignment of the Ministry of Education and Science
of the Russian Federation No. 1163 – Russia.
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Background: Lung cancers are characterized by the genetic
alterations that often affect a common group of oncogenic signal-
ing pathways. Identification of biologically significant genetic
alterations in lung cancer that lead to activation of oncogenes
and inactivation of tumor suppressor genes has the potential to
provide further therapeutic opportunities (Cooper, 2013). In this
context, it is important that molecular aberrations may act as
negative predictors of sensitivity to treatment. The discovery of
driver oncogenes, such as activating mutations in the epidermal
growth factor receptor gene (EGFR), has made personalized med-
icine for lung cancer a reality. Despite the high initial results,
NSCLC patients acquire resistance to tyrosine kinase inhibitors
in the worldwide. There are several findings suggesting that the
effect of tyrosine kinase inhibitors could be limited to patients
harboring KRAS mutation. To date, a limited information
regarding link of morphological portrait of adenocarcinomas with
bearing of simultaneously concurrent mutations of KRAS and
EGFR genes. The detection of concurrent gene mutation is usually
carried out in a mixture of tumor cells. We plan to analyze EGFR
and KRAS mutations in all clonal components (or morphological
structures) of NSCLC tumors isolated by laser microdissection.
So, we suggest that NSCLC clonal components might bear two
concurrent EGFR and KRASmutations simultaneously or different
clonal components might bear either EGFR or KRAS mutations.
The data obtained can predict resistance to EGFR-TKIs and affect
therapeutic decision making.
Materials and methods: The tumor samples were obtained
from archived formalin-fixed paraffin-embedded tissue blocks.
Paraffin was removed by xylene extraction, and the sample was
subsequently lysed by proteinase K. The region containing the
highest percentage of tumor cells (at least 50%) was dissected.
Microscopes Axio Scope A1 and Axio Star plus (Carl Zeiss, Ger-
many) was used to perform histological analysis. If necessary,
tumour cells were carefully selected and removed from the sam-
ples by laser microdissection using a P.A.L.M. microlaser instru-
ment (PALM AdhesiveCaps, P.A.L.M., Bernried, Germany). EGFR
(exon 19 deletion and 21 L858R) and KRAS (Gly12Cys, Gly12Ser,
Gly12Arg, Gly12Val, Gly12Asp, Gly12Ala, Gly13Asp) gene
amplification was based on RT-PCR on CFX96 Real-Time System
(Bio-Rad).
Results: A total of 115 patients with stage (IIIB–IV) of NSCLC
with EGFR-TKI- sensitive mutations were eligible for the analysis.
A rare coexistence of KRAS and EGFR mutations were observed in
3 patients (2.6%). The first sample was described as nonmucinous
solid adenocarcinoma and has deletion of 19 exon of EGFR gene
and G12C mutation of KRAS gene. The second sample was
described as mucinous lepidic adenocarcinoma and has deletion
of 19 exon of EGFR gene and G12D mutation of KRAS gene. The
third sample was described as mucinous adenocarcinoma with
solid and acinar monoclonal components and also has deletion
of 19 exon of EGFR gene and G12C mutation of KRAS gene. Of
all the samples, only one had two different monoclonal compo-
nents. Unfortunately, this sample was not available due to biopsy
and few numbers of cells for microdissection. Fiala et al. (2013)
reported that KRAS mutations were not only as a negative
prognostic factor and also as a biomarker predicting resistance
to EGFR-TKIs, especially G12C. Patient with nonmucinous solid
adenocarcinoma with deletion of 19 exon and G12C (EGFR and
KRAS genes, respectively) is unlikely to benefit from receiving
gefitinib or erlotinib.
Conclusion: The data obtained show that further studies are
required to improve personalized therapy for NSCLC patients.
The frequency and type of KRAS and EGFR mutations were first
assessed in NSCLC patients from West Siberia.
This work was supported by a Grant from the OPTEK Company
(No 122/2014/51/Nvs).
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Novel monoclonal antibodies to C-terminal end of transmembrane
prostate androgen-induced protein (TMEPAI) for evaluation of its role
in gastric cancer prognosis
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